[Axitinib in real life, analysis of our results.]

Abstract

OBJECTIVE:

Following first-line treatment progression in metastatic renal carcinoma, different options for second-line treatment are available, with axitinib being one of them. The objective of this article is to evaluate the results of Axitinib in a real practice setting. METHODS: From December 2011 to October 2016, we treated 19 patients with CCRM with Axitinib, 3 patients in third line and 16 patients in second line after progression on Sunitinib or Pazopanib. We performed a retrospective study of the last 16 patients, analyzing the effectiveness and safety of the drug. RESULTS: The median progression-free survival (PFS) was 9 months and the median overall survival with 8 dead patients was 59 months. Overall, toxicity by Axitinib was very common, diarrhea 87.5%, asthenia 75%, dysphonia 56.25%, hypertension 37.5% and anorexia 37.5%, although most are grade 1-2 toxicities controlled with hygiene-diet measures and treatment recommendations. CONCLUSIONS: Axitinib is a drug that has been shown to increase PFS after 1st line progression, with a tolerable toxic profile. With the approval of nivolumab and cabozantinib, the place of Axitinib in sequential therapy is yet to be defined.

• Authors: Clemencia Varilla-Varilla, Fernando Vázquez Alonso, Casandra Hernández Hernández, Manuela Exposito Ruiz, José Manuel Cozar Olmo
• Journal: Archivos espanoles de urologia (Arch Esp Urol) Vol. 72 Issue 4 Pg. 360-366 (May 2019) ISSN: 0004-0614 [Print] Spain
• Vernacular Title: Axitinib en el tratamiento del cáncer renal metastásico en la vida real, análisis de nuestros resultados.
• PMID: 31070131 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Imidazoles
• Indazoles
• Axitinib

Topics

• Antineoplastic Agents (therapeutic use)
• Axitinib (therapeutic use)
• Carcinoma, Renal Cell (drug therapy)
• Humans
• Imidazoles
• Indazoles
• Kidney Neoplasms (drug therapy)
• Retrospective Studies
• Treatment Outcome